Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ethambutol Hydrochloride

FDA-approved product (tablet, oral), marketed as Ethambutol Hydrochloride, Myambutol.

Registered studies
50+
Lab records
52
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Ethambutol Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Pulmonary tuberculosis
  • Tuberculosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other drugs for treatment of tuberculosis
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04AK02

Repurposing investigation

Ethambutol Hydrochloride is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA20.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli10.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae9.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis33.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 46 of 52 lab records
Open Ethambutol Hydrochloride in ChEMBL Registered studies below
Show the 52 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ethambutol Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis

    NCT00376012 · start 2001-02

    Registered record
    Registry ID
    NCT00376012
    Conditions
    Tuberculosis; Human Immunodeficiency Virus Infections
    Interventions
    Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide); Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2001-02
    Completion
    2008-09
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Human Immunodeficiency Virus Infections
    InterventionAnti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide); Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)
    PhasePhase 3
    Registry statusUnknown

  • The Safety and Effectiveness of Clarithromycin Plus Ethambutol Used With or Without Clofazimine in the Treatment of MAC in Patients With AIDS

    NCT00002331 · start 1994-01

    Registered record
    Registry ID
    NCT00002331
    Conditions
    Mycobacterium Avium-intracellular Infection; HIV Infections
    Interventions
    Ethambutol hydrochloride; Clarithromycin; Clofazimine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    1994-01
    Completion
    1995-03
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycobacterium Avium-intracellular Infection; HIV Infections
    InterventionEthambutol hydrochloride; Clarithromycin; Clofazimine
    PhaseNot applicable
    Registry statusCompleted

  • A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.

    NCT00000796

    Registered record
    Registry ID
    NCT00000796
    Conditions
    HIV Infections; Tuberculosis
    Interventions
    Cycloserine; Ethionamide; Capreomycin sulfate; Aminosalicylic acid; Streptomycin sulfate; Ethambutol hydrochloride; Amikacin sulfate; Isoniazid; Pyrazinamide; Pyridoxine hydrochloride; Levofloxacin; Rifampin; Clofazimine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1998-10
    Enrolment
    525

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Tuberculosis
    InterventionCycloserine; Ethionamide; Capreomycin sulfate; Aminosalicylic acid +9 more
    PhaseNot applicable
    Registry statusCompleted

  • Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis

    NCT00000950

    Registered record
    Registry ID
    NCT00000950
    Conditions
    HIV Infections; Tuberculosis
    Interventions
    Ethambutol hydrochloride; Isoniazid; Pyrazinamide; Pyridoxine hydrochloride; Rifampin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Tuberculosis
    InterventionEthambutol hydrochloride; Isoniazid; Pyrazinamide; Pyridoxine hydrochloride +1 more
    PhaseNot applicable
    Registry statusCompleted

  • Evaluation of Treatment for Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients

    NCT00001039

    Registered record
    Registry ID
    NCT00001039
    Conditions
    Mycobacterium Avium-intracellulare Infection; HIV Infections
    Interventions
    Ethambutol hydrochloride; Clarithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2002-06
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycobacterium Avium-intracellulare Infection; HIV Infections
    InterventionEthambutol hydrochloride; Clarithromycin
    PhasePhase 2
    Registry statusCompleted